Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Conditions
Interventions
Dihydroergotamine
Placebo
Locations
127
United States
MD First Research
Chandler, Arizona, United States
Elite Clinical Studies
Phoenix, Arizona, United States
Alliance For Multispecialty Research
Tempe, Arizona, United States
Cognitive Clinical Trials, LLC
Tempe, Arizona, United States
Clinedge, LLC
Tucson, Arizona, United States
ERG Clinical
Little Rock, Arkansas, United States
Start Date
June 30, 2021
Primary Completion Date
October 13, 2022
Completion Date
October 26, 2022
Last Updated
November 27, 2023
NCT06735833
NCT06241313
NCT06641466
NCT07018713
NCT04715685
NCT07476053
Lead Sponsor
Satsuma Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions